Sonoma PharmaceuticalsSNOA
13F holders, Q3 2025 (September 30)20holders +6
8new positions
2sold out
$3.88avg. 13F price*
At the end of Q3 2025, 20 institutions reported holding Sonoma Pharmaceuticals Inc. (SNOA) in their 13F filings, up 6 from Q2 2025. 8 opened new positions and 2 sold out. The largest holders were Vanguard Group Inc. ($81K), Geode Capital Management, LLC ($68K) and DRW Securities, LLC ($66K).
- Company
- Sonoma Pharmaceuticals Inc.
- CUSIP
- 83558L303
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $154K |
| Exits | 2 | $147K |
All 13F filers, Q2 2025 → Q3 2025: 40,349 shares bought and 65,891 shares sold, net −25,542 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 20 holders
| Vanguard Group Inc. | 0.00% | New | 20,873 | $81K |
| Geode Capital Management, LLC | 0.00% | No change | 17,617 | $68K |
| DRW Securities, LLC | 0.00% | New | 17,070 | $66K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +53.6% | 1,536 | $6K |
| Citigroup Inc. | 0.00% | New | 656 | $3K |
| Rockefeller Capital Management L.P. | 0.00% | New | 646 | $3K |
| Global Retirement Partners, LLC | 0.00% | New | 438 | $2K |
| MAI Capital Management | 0.00% | New | 124 | $482 |
| JPMorgan Chase & Co. | 0.00% | Add +2.5% | 123 | $477 |
| BlackRock, Inc. | 0.00% | No change | 113 | $438 |
| UBS Group AG | 0.00% | Reduce -99.3% | 108 | $419 |
| US Bancorp \de | 0.00% | No change | 25 | $97 |
| Bank of America Corp. | 0.00% | No change | 17 | $66 |
| Morgan Stanley | 0.00% | No change | 4 | $16 |
| Allworth Financial LP | 0.00% | No change | 3 | $12 |
| Quaker Wealth Management, LLC | 0.00% | No change | 3 | $12 |
| FMR LLC | 0.00% | New | 2 | $7 |
| Danske Bank A/S | 0.00% | No change | 1 | $4 |
| SBI Securities Co., Ltd. | 0.00% | New | 1 | $4 |
| Cwm, LLC | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is SNOA's weight in each manager's 13F, not the share of Sonoma Pharmaceuticals Inc. the manager owns.